27.96
  Price4.06%   +1.09
(After Hours: 28.48 +0.52 +1.86%)
Apr-15-21 12:29PM ‘Natural Killer Cells’ and Other Promising Cancer TreatmentsBarrons.com
Apr-12-21 08:37AM Should You Take Comfort From Insider Transactions At Rubius Therapeutics, Inc. (NASDAQ:RUBY)?Simply Wall St.
08:00AM Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive CancersGlobeNewswire
Apr-09-21 08:00AM Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual MeetingGlobeNewswire
Mar-30-21 09:30AM Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial OfficerPR Newswire
Mar-27-21 08:42AM Rubius Therapeutics Charts A New Path For Hard-To-Treat CancersTipRanks
Mar-18-21 06:16AM 3 Biotech Stocks to Avoid Right NowMotley Fool
Mar-17-21 08:36AM Implied Volatility Surging for Rubius Therapeutics (RUBY) Stock OptionsZacks
01:15AM Rubius Therapeutics: Promising Cancer Treatment Data De-Risks PipelineTipRanks
Mar-16-21 09:28AM Rubius Therapeutics Prices Upsized Public Offering of Common StockGlobeNewswire
08:50AM Company News for Mar 16, 2021Zacks
Mar-16-21 08:17AM The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine StudyBenzinga
Mar-15-21 04:32AM Rubius Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire
04:30AM Rubius Stock Flies To Record High After Experimental Cancer Drug Proves ItselfInvestor's Business Daily
Mar-15-21 02:06AM Rubius Therapeutics Stock Trading Higher On Positive Efficacy, Safety RTX-240 Data In Solid Tumor StudyBenzinga
01:34AM Why Rubius Therapeutics Stock Is Skyrocketing TodayMotley Fool
Mar-15-21 11:40AM Rubius Stock Flies To Record High After Experimental Cancer Drug Proves ItselfInvestor's Business Daily
09:14AM Rubius Doubles on Progress in Early-Stage Cancer-Drug TrialTheStreet.com
Mar-15-21 07:39AM Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent ActivityGlobeNewswire
Mar-13-21 06:56AM 3 Biotech Stocks That Have Already Rocketed Higher in 2021Motley Fool
Mar-12-21 04:30AM Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid TumorsGlobeNewswire
Mar-10-21 04:30AM Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual MeetingGlobeNewswire
Feb-18-21 08:00AM Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswire
Feb-09-21 08:00AM Rubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewswire
Feb-03-21 04:45AM Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology DaysGlobeNewswire
Jan-11-21 08:00AM Rubius Therapeutics Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
Jan-04-21 04:01AM Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
Dec-10-20 10:33AM Is Rubius (RUBY) A Good Stock To Buy Now?Insider Monkey
Nov-30-20 04:00AM Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx ConferenceGlobeNewswire
Nov-10-20 04:01AM Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare ConferenceGlobeNewswire
Nov-09-20 08:05AM Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the PipelineGlobeNewswire
08:00AM Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual MeetingGlobeNewswire
Nov-05-20 08:00AM Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240GlobeNewswire
Oct-29-20 04:30AM Rubius Therapeutics to Announce Third Quarter 2020 Financial ResultsGlobeNewswire
Oct-28-20 05:00AM Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of ActionGlobeNewswire
Oct-15-20 08:00AM Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual MeetingGlobeNewswire
Oct-13-20 08:19AM Are Insiders Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Stock?Simply Wall St.
Sep-29-20 04:01AM Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy SummitGlobeNewswire
Sep-28-20 08:00AM Rubius Therapeutics Appoints Jose Carmona as Chief Financial OfficerGlobeNewswire
Sep-22-20 06:55AM 3 High-Risk, High-Reward Stocks to Add to Your Watch ListMotley Fool
Sep-08-20 04:01AM Rubius Therapeutics to Participate at Upcoming Investor ConferencesGlobeNewswire
Aug-10-20 08:00AM Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across PipelineGlobeNewswire
Aug-03-20 04:01AM Rubius Therapeutics to Announce Second Quarter 2020 Financial ResultsGlobeNewswire
Jul-07-20 08:00AM Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene WritingPR Newswire
Jun-30-20 08:00AM Rubius Therapeutics Provides Update on Clinical Trial Progress for its Lead Oncology Product Candidate RTX-240 and Announces Planned Leadership TransitionGlobeNewswire
Jun-22-20 08:00AM Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Association of Cancer Research Virtual Annual Meeting IIGlobeNewswire
Jun-01-20 11:31AM Hedge Funds Are Selling Rubius Therapeutics, Inc. (RUBY)Insider Monkey
May-28-20 08:00AM Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of CellarityPR Newswire
May-26-20 04:01AM Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare ConferenceGlobeNewswire
May-15-20 08:00AM Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers at the American Association of Cancer Research Annual MeetingGlobeNewswire
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Cap:    |  Volume (24h):